ATE451103T1 - Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält - Google Patents

Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Info

Publication number
ATE451103T1
ATE451103T1 AT04768663T AT04768663T ATE451103T1 AT E451103 T1 ATE451103 T1 AT E451103T1 AT 04768663 T AT04768663 T AT 04768663T AT 04768663 T AT04768663 T AT 04768663T AT E451103 T1 ATE451103 T1 AT E451103T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
treatment
composition
containing candesartan
atherosclerosis containing
Prior art date
Application number
AT04768663T
Other languages
English (en)
Inventor
Jay Mehta
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE451103T1 publication Critical patent/ATE451103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
AT04768663T 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält ATE451103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
PCT/GB2004/004120 WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Publications (1)

Publication Number Publication Date
ATE451103T1 true ATE451103T1 (de) 2009-12-15

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768663T ATE451103T1 (de) 2003-09-26 2004-09-22 Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält

Country Status (28)

Country Link
US (2) US7932263B2 (de)
EP (1) EP1673091B1 (de)
JP (1) JP4841433B2 (de)
KR (1) KR101129767B1 (de)
CN (1) CN100515421C (de)
AT (1) ATE451103T1 (de)
AU (1) AU2004275567B2 (de)
BR (1) BRPI0414724A (de)
CA (1) CA2540102C (de)
CY (1) CY1109814T1 (de)
DE (1) DE602004024555D1 (de)
DK (1) DK1673091T3 (de)
ES (1) ES2336450T3 (de)
GB (1) GB0322552D0 (de)
HR (1) HRP20100080T1 (de)
IL (1) IL174536A (de)
IS (1) IS2729B (de)
MX (1) MXPA06003353A (de)
NO (1) NO335813B1 (de)
NZ (1) NZ546162A (de)
PL (1) PL1673091T3 (de)
PT (1) PT1673091E (de)
RU (1) RU2358737C2 (de)
SG (1) SG145773A1 (de)
SI (1) SI1673091T1 (de)
UA (1) UA90249C2 (de)
WO (1) WO2005030215A2 (de)
ZA (1) ZA200602433B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
BR112012006939A2 (pt) * 2009-09-29 2015-09-08 Butamax Tm Advanced Biofuels célula hospedeira de produção de levedura recombinante e método para a produção de um produto selecionado do grupo que consiste em 2,3-butanodiol, isobutanol, 2-butanol, 1-butanol, 2-butanona, valina, leucina, ácido lático, ácido málico, álcool, isoampilico e isoprenoides
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
EP2787993B1 (de) * 2011-12-09 2016-11-23 Artskin D.O.O. Behandlung von arterienwänden durch kombination eines raas-inhibitors und eines hmg-coa-reduktaseinhibitors
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
KR102055894B1 (ko) * 2016-11-15 2019-12-13 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
EP0754042A4 (de) 1994-03-29 2004-06-23 Merck & Co Inc Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
NZ330774A (en) 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
HU225415B1 (en) * 1996-07-15 2006-11-28 Sankyo Co Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
YU2700A (sh) 1997-08-29 2002-06-19 Pfizer Products Inc. Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0009739A (pt) 1999-04-13 2002-04-09 Basf Ag Composto, medicamento, preparação farmacêutica, e, usos de um elemento estrutural, de um composto e de uma preparação farmacêutica
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1314425A4 (de) * 2000-08-30 2004-06-02 Sankyo Co Medizinische zusammenstellung zur prophylaxe und behandlung von herzversagen
JP2002145770A (ja) 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1385548B1 (de) 2001-01-26 2007-05-23 Schering Corporation Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US20030053950A1 (en) * 2001-04-18 2003-03-20 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100824193B1 (ko) * 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
CN100515421C (zh) 2009-07-22
IL174536A (en) 2010-12-30
DK1673091T3 (da) 2010-03-22
CA2540102A1 (en) 2005-04-07
US20070275989A1 (en) 2007-11-29
BRPI0414724A (pt) 2006-11-21
IL174536A0 (en) 2008-04-13
KR101129767B1 (ko) 2012-03-26
KR20060108623A (ko) 2006-10-18
IS8421A (is) 2006-04-21
GB0322552D0 (en) 2003-10-29
ZA200602433B (en) 2007-06-27
CN1886136A (zh) 2006-12-27
EP1673091A2 (de) 2006-06-28
NZ546162A (en) 2008-11-28
ES2336450T3 (es) 2010-04-13
RU2358737C2 (ru) 2009-06-20
JP2007506720A (ja) 2007-03-22
JP4841433B2 (ja) 2011-12-21
CA2540102C (en) 2012-07-24
RU2006113366A (ru) 2007-11-10
PT1673091E (pt) 2010-02-15
IS2729B (is) 2011-04-15
SG145773A1 (en) 2008-09-29
NO20061744L (no) 2006-06-22
WO2005030215A3 (en) 2005-06-02
NO335813B1 (no) 2015-02-23
DE602004024555D1 (de) 2010-01-21
US20110046119A1 (en) 2011-02-24
SI1673091T1 (sl) 2010-03-31
PL1673091T3 (pl) 2010-04-30
EP1673091B1 (de) 2009-12-09
US7932263B2 (en) 2011-04-26
UA90249C2 (uk) 2010-04-26
HK1090553A1 (en) 2006-12-29
AU2004275567A1 (en) 2005-04-07
CY1109814T1 (el) 2014-09-10
AU2004275567B2 (en) 2008-01-10
WO2005030215A2 (en) 2005-04-07
HRP20100080T1 (hr) 2010-04-30
MXPA06003353A (es) 2006-06-08

Similar Documents

Publication Publication Date Title
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
BR0317715A (pt) Composições e processos de uso de collajolie
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
SE0203752D0 (sv) New compounds
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2004018431A3 (en) Novel phenanthridines
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE69939481D1 (de) Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
NO20055741D0 (no) Nye kjemiske forbindelser
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
ATE350061T1 (de) Zusammensetzung zur behandlung von virusinfektionen, die einen calcium-kanal-blocker und ein chinolin enthält
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
NO20053562L (no) Nye aminobenzofenonforbindelser
ATE390144T1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673091

Country of ref document: EP